Cellular origin of the tissue scarring caused by organ damage associated with diabetes, lung disease, high blood pressure, kidney disease and other conditions has been identified by Harvard Stem Cell Institute scientists at Brigham and Women's Hospital. The buildup of scar tissue is known as fibrosis.
Fibrosis has a number of consequences, including inflammation, and reduced blood and oxygen delivery to the organ. In the long term, the scar tissue can lead to organ failure and eventually death. It is estimated that fibrosis contributes to 45 percent of all deaths in the developed world.
The researchers, led by Benjamin Humphreys, MD, PhD, found that a rare population of stem cells located outside of blood vessels in mice become myofibroblast cells that secrete proteins that cause scar tissue.
Killing these stem cells prevents the deadly complications of fibrosis, the researchers report today in the journal Cell Stem Cell
online. Rafael Kramann, MD, a postdoctoral fellow in Humphreys' lab, is the first author on the paper.
"Under normal circumstances, myofibroblasts stimulate wound healing, but when there's an ongoing injury to an organ (e.g., the liver of a hepatitis C patient, the heart of a patient with high blood pressure, or the kidney of a patient with diabetes) these proteins clog up normal functioning," said Humphreys, a Harvard Medical School associate professor at Brigham and Women's Hospital, who leads the Harvard Stem Cell Institute Kidney Program.
The researchers are now in discussions with a pharmaceutical firm about screening for drugs that might target and shut off these fibrosis-causing stem cells in cases of chronic organ disease. The idea of using the stem cells as targets for drug discovery began with the formation by Humphreys, Kramann, and Derek DiRocco, PhD, of MatriTarg Laboratories--the 2013 Harvard Dean's Health and Life Sciences Challenge winning startup.
"We wanted to know if eradication of this very small population of stem cells would improve organ function, and both kidney and heart were completely protected from developing fibrosis-related complications (e.g., kidney failure and heart failure)," said Humphreys, who also heads the Onco-Nephrology Program at the Dana-Farber Cancer Institute. "This provides an important proof of principal that drugs that target the stem cells could be therapeutic."
The cellular origin of kidney fibrosis has long puzzled researchers. It was unknown which kinds of stem cells form myofibroblasts, and where these stem cells are located. One long-held hypothesis was that the stem cells that give rise to myofibroblasts are found in the bone marrow, but Humphreys' research disproves that. By tagging a specific protein called Gli1 expressed by the myofibroblast-forming stem cells, the scientists showed that the cells are found on the periphery of blood vessels and they also reside within organs.
Humphreys does caution that the cell population his lab found is responsible for about 60 percent of all organ myofibroblasts, which means that they seem to be the most dominant source, but that there may be other cells that also contribute to the myofibroblast population.
"We haven't disproven every hypothesis and our results do leave room for other cells that might contribute to fibrosis," he said.
The Humphreys Lab collaborated with fellow Harvard Stem Cell Institute member Benjamin Ebert, MD, also at Brigham and Women's Hospital, on the work.